Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8998457 | Neuropharmacology | 2005 | 8 Pages |
Abstract
Our results confirm previous findings that pharmacological inactivation of A2A receptors inhibits MPTP-induced dopaminergic damage at the level of striatum. In addition, we demonstrate for the first time that, after MPTP treatment in mice, an A2A antagonist is neuroprotective, and has anti-inflammatory effects, at the level of the substantia nigra. Thus, our data further support the use of A2A receptor antagonists as a novel neuroprotective therapy for PD.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Mette Pierri, Elisabetta Vaudano, Thomas Sager, Ulrica Englund,